For HCPs, Request Your Two-week Kardia 12L Trial Today | Inquire Now

AliveCor Logo

Our Technology

Our Devices

Kardia 12L

New

KardiaMobile 6L
K1000 (Instant QT)
KardiaMobile

Our Software

KardiaPro
KardiaStation
KardiaComplete
API & SDK Solutions
RPM & CCM Solutions
Our AI

Our Solutions

For Physicians & Providers
For Health Systems & Clinics

For Life Sciences Industry

Clinical Trials
Patient Engagement
For Employers
For Emergency Medical Services
For Veterans Affairs
For Payors
For Consumers

About

Mission
Leadership
The Human Component Film
Newsroom

Resources

Clinical Evidence

Publications
Case Studies

Technical Resources

Kardia 12L
KardiaMobile 6L
KardiaPro
KardiaStation
AliveCor K1000
Reimbursement

Industry Insights

Our Blogs
Testimonials
Learning Library

Events

Webinars
Upcoming Events
Past Events
(855) 338-8800
AliveCor Logo
AliveCor Logo
  • Instagram
  • Facebook
  • Twitter
  • LinkedIn
    • (855) 338-8800
    • Mission
    • Careers
    • Research
    • Newsroom
    • FAQs
    • User Manuals
    • Compatibility
    • Shipping
    • (855) 338-8800
    • KardiaMobile Card
    • KardiaMobile 6L
    • KardiaMobile
    • KardiaCare
    • International
  • Instagram
  • Facebook
  • Twitter
  • LinkedIn
  • Privacy Policy
  • Security
  • Telehealth Informed Consent
  • Terms
  • Accessibility

©2024 AliveCor, Inc. All Rights Reserved. Patents www.alivecor.com/patents. AliveCor and Kardia are trademarks of AliveCor, Inc. in the United States and other countries. Apple is a trademark of Apple, Inc. registered in the U.S. and other countries. App Store is a service mark of Apple, Inc. Android is a trademark of Google Inc. Google Play is a trademark of Google Inc.

biopharma-2biopharma-3biopharma-4

On-Demand Webinar

Reinventing Cardiac Monitoring in Clinical Trials: AI, Safety, and Data Impact

Cardiac monitoring advancements are transforming clinical trials—enhancing data collection and delivery to improve efficiency and accuracy in clinical trials.

Discover the highlights from our fireside chat with leading experts.

biopharmaNew.list.one.name

Todd Rudo, MD

EVP, Chief Medical Officer

biopharmaNew.list.one.name
biopharmaNew.list.two.name

Mark Matson

Senior Director, Sensor Cloud

biopharmaNew.list.two.name
biopharmaNew.list.three.name

David E. Albert, MD

Founder, Chief Medical Officer

biopharmaNew.list.three.name

Insights from the Fireside Chat

TOPIC 1

How Can Patient-Centric Cardiac Monitoring Enable Decentralized and Hybrid Trials?

Recent FDA guidance on digital health technologies and decentralized trials has influenced the greater adoption and implementation of advanced ECG monitoring in clinical research. Explore how patient-centered monitoring advancements support these trial models, delivering real-time data opportunities and optimizing workflows.

TOPIC 2

How Can We Streamline Workflows and Drive Operational Efficiency?

When it comes to data, more is more. Learn how these evolving trial models deliver data that supports advanced AI , streamline data science, and ultimately lead to better outcomes.

TOPIC 3

How Can We Harness AI for More Accurate Data?

AI is revolutionizing the accuracy and efficiency of data analysis in clinical trials. Explore how AI -powered ECG technologies are enhancing data quality and streamlining operations.

Unlock More Insights

Find out how innovative cardiac monitoring solutions can transform your clinical trial with our free guide.

get my guide
Unlock More Insights

Blog

Why Portable 6-Lead Devices Are the Future of Cardiac Monitoring in Clinical Trials

QT determinations are essential in clinical trials, but collecting them is challenging. Discover how the 6-lead device alleviates these challenges for more flexible and patient-centric trials.

Remote Monitoring Boosts Decentralized Trials

PharmExec.com | Decentralized trials are known to have positive effects, but sponsors have concerns about how to monitor patients well. Remote patient monitoring (RPM) solutions, like those from AliveCor, are changing this paradigm. The benefits that decentralized trials offer patients and sponsors are evident. Yet, decentralized trials are still lacking.

JAMA Study Shows a 6-Lead Device Could Reduce the Need to Perform a 12-Lead ECG In Resource Limited Settings

At a QTc interval threshold of 500 milliseconds, the 6-lead device had a high negative predictive value of 99.8% and was an effective triage test. This validation is pivotal for sponsors aiming to deliver quality data while alleviating common cardiac monitoring challenges.